KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Payables (2016 - 2025)

Historic Payables for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $432.0 million.

  • Biogen's Payables fell 9357.14% to $432.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $432.0 million, marking a year-over-year decrease of 9357.14%. This contributed to the annual value of $432.0 million for FY2025, which is 9357.14% down from last year.
  • Latest data reveals that Biogen reported Payables of $432.0 million as of Q4 2025, which was down 9357.14% from $6.7 billion recorded in Q3 2025.
  • Over the past 5 years, Biogen's Payables peaked at $7.9 billion during Q4 2021, and registered a low of $375.3 million during Q2 2021.
  • Over the past 5 years, Biogen's median Payables value was $6.7 billion (recorded in 2024), while the average stood at $5.4 billion.
  • In the last 5 years, Biogen's Payables tumbled by 9519.32% in 2021 and then surged by 195488.94% in 2022.
  • Quarter analysis of 5 years shows Biogen's Payables stood at $7.9 billion in 2021, then dropped by 13.86% to $6.8 billion in 2022, then grew by 8.4% to $7.3 billion in 2023, then fell by 8.47% to $6.7 billion in 2024, then crashed by 93.57% to $432.0 million in 2025.
  • Its last three reported values are $432.0 million in Q4 2025, $6.7 billion for Q3 2025, and $6.7 billion during Q2 2025.